COVID-19 and Its Impact on the Total Testing Cycle
The Journal of Applied Laboratory Medicine · 2023
DOI: 10.1093/jalm/jfad075 ↗Kurz gefasst
Editorial in der Zeitschrift The Journal of Applied Laboratory Medicine, 2023. Verfasst von David N Alter. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, United States. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
The study “Robust Response of the Clinical Laboratory to the COVID-19 Pandemic Despite Significant Challenges” in this issue of JALM (1) identifies and demonstrates by use of serial surveys what clinical laboratories encountered when shouldering the burden of SARS-CoV-2 testing over the course of the COVID-19 pandemic. Use of repeat surveys, instead of “spot” surveys, allowed the authors to paint a picture of how these issues changed over time. Laboratorians were anecdotally aware a priori of their findings based on individual experiences; professional society communications; personal discussions amongst themselves and of course, what was splayed out in the media over a never-ending 24/7 news cycle. This study and the ones cited document where lie clinical laboratory critical vulnerabilities and demonstrate how important is the modern clinical laboratory to contemporary clinical medicine; regardless of global mass casualty event, or not. We learned from the study and our personal experiences exactly how vulnerable is the clinical laboratory at every phase (pre-analytic, analytic, and post-analytic) of the total laboratory testing cycle. Pre-analytically, a regulatory weakness was identified when many of us learned in declared public health emergencies that conventional practices used for development and validation of laboratory-developed tests (LTDs) are blocked by additional layers of regulatory burden including FDA approval in the form of an “Emergency Use Authorization” (EUA) (2–4). This extra hurdle slowed down, by several weeks, local development and utilization of COVID-19 testing strategies. On the other hand, the pandemic also identified a regulatory strength. At its outset, the Centers for Disease Control and Prevention (CDC) distributed test kits for COVID-19 testing; however, existing Clinical Laboratory Improvement Amendments (CLIA) verification requirements (5) identified problems with these kits disallowing their use (6). These verification requirements are mandated for every CLIA-certified laboratory when introducing a new test and helped avoid an additional entirely new dimension of test-related problems. In November 2020, it was reported that the CDC was aware of these testing problems prior to release but released them anyway (7). Both of those issues gave every non-laboratory-related citizen a taste for what is required for implementation of new laboratory testing, whether it be FDA approved or not. Getting past that obstruction took several weeks as the FDA revised its EUA practice to handle the marked need for COVID-19 testing. As it was being revised and afterwards, the FDA received many submissions for COVID-19 test methods from established clinical laboratories (hospital-based and commercial) to not as well-known/unknown ones that appeared almost overnight offering COVID-19 testing. Either way, clinical laboratories and patient care were behind the curve for testing solutions for the first several weeks as they progressed through the initial test development phase (3). Once the LDT/EUA issue was resolved, laboratories ran into rate-limiting supply chain issues; most notably swabs for nasal specimen collection. As we progressed through the pandemic, supply-related issues continued and began to spike secondary to a perfect storm of markedly increased testing and resource issues associated with both domestic and overseas suppliers of reagents and specimen collection devices (8). From an analytic phase perspective, there was discussion and debate with respect to best specimen type (nasal swab, saliva, or blood), test type (antigen vs antibody, serology, and PCR) and available test platform (9, 10). All of which ultimately settled down into the practices currently used and recommended. Post-analytic concerns were also identified with result interpretation: could results be used to monitor degree of infectivity and disease burden? For example, did the strength of a serologic response or PCR Ct (cycle threshold) value correlate with degree of symptomaticity and/or infectivity? In summation, in the early stages of the pandemic, as demonstrated in the survey, across the total testing cycle, there were not many known knowns but a lot of known unknowns and too many unknown unknowns. The COVID-19 pandemic demonstrated to the world the importance of laboratory testing in clinical medicine. During this time period, hospital admissions included a COVID-19 test to rule in/rule out infection as cause of presenting complaint or to modify treatment if COVID-19 infection was a co-morbid factor. The clinical laboratory became responsible for a majority of medical decision-making, demonstrating its importance to all of modern clinical medicine. Never before could the argument be made that a single test was involved with clinical decision-making across most medical conditions. The global community also had an abrupt awakening as to how important is the clinical laboratory via the need for COVID-19 testing. Without effective, efficient, and available laboratory testing, the global public health response would have been paralyzed, unable to assess the pandemic’s extent and depth in all but the most extreme and/or fatal cases. Debates about the importance of testing or not were specious and comments such as “…testing makes us look bad…” or “…when you test, you create cases…” (11) increased risk to at-risk individuals because of the large proportion of asymptomatic/mildly symptomatic cases. Testing was necessary to determine pandemic extent in the latter group. A linchpin of pandemic control, any pandemic, has to be determination as to who has contagion and who does not (12, 13). This study does not address the laboratory pressures secondary to increased volume of routine testing due to the overall increased number of admissions. Neither does it address the increase in testing specifically required for the COVID-19 patient, such as individuals presenting with COVID-19-like symptoms needing to be evaluated for other respiratory diseases or COVID-19 patients requiring specialized testing associated with the infection itself, e.g., increased hemostasis assay testing volume for COVID-19-associated hypercoagulablity. At my institution, we explored alternative viscosity assays due to the increase in viscosity testing and had to validate our thromboelastography method for the COVID-19 patient. Overall, we all experienced how unprepared was the medical industrial complex for a global pandemic. In this paper, we specifically see how a pandemic impacted the laboratory total testing cycle. It is not necessary to restate details of what happened in terms of regulatory hurdles, supply chain shortages, assay/instrument availability, best appropriate testing, problems with staffing, and any other impact that can be added to that list. What is important to relate is how all of these issues became evident on the public stage via medical media pundits, all of whom initially were not laboratorians but experts in other fields such as infectious disease, epidemiology, cardiology, and even radiology! In fact, the predominant cognate professional organization, the American Society of Microbiology, was initially not heard from in public forums. Neither included in the public discussion were other preeminent laboratory medicine-related organizations: the American Association of Clinical Chemistry, College of American Pathologists, and the American Society of Clinical Pathology. However, all were in the thick of it, on a daily basis, working and communicating with CDC, FDA, and lawmakers as well as their members and member laboratories to insure that clinical laboratories were operating to provide the best laboratory testing available (14). Laboratory test experts were not often seen in the media, interviewed by a network commentator, or even regularly represented at one of many daily press conferences. In some respects, laboratory medicine was confined to the basement during this event. For example, it was not until summer 2020 that the AACC was invited to be part of Admiral Giroir’s White House Coronavirus Taskforce National Testing Implementation Forum and it was not until December 2020, that the “paper of record,” the New York Times, reported on the plight of laboratory technical staff (15). Ultimately, the AACC’s contributions were recognized in 2021 with a “Power of A” award from the American Society of Association Executives (ASAE) for its efforts in stemming the course of COVID-19 during the pandemic. Where do we go from here? We have seen how it occurred. We have the evidence of what we saw and it has been very carefully documented. When the next global mass casualty event occurs, will we have learned these lessons and be better prepared with more nimble responses and layered, alternative strategies of response? I hope so. Author Contributions:The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Authors’ Disclosures or Potential Conflicts of Interest:Upon manuscript submission, all authors completed the author disclosure form. Research Funding: None declared. Disclosures: D. Alter is currently President of the Management Sciences and Patient Safety Division of ADLM and received a trip allowance for the 2023 AACC Annual Scientific Meeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, United States.
Zitieren
APA
Alter, D. N. (2023). COVID-19 and Its Impact on the Total Testing Cycle. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfad075
Vancouver
Alter DN. COVID-19 and Its Impact on the Total Testing Cycle. The Journal of Applied Laboratory Medicine. 2023. doi:10.1093/jalm/jfad075
BibTeX
@article{Alter2023,
author = {Alter, David N},
title = {COVID-19 and Its Impact on the Total Testing Cycle},
journal = {The Journal of Applied Laboratory Medicine},
year = {2023},
doi = {10.1093/jalm/jfad075}
}
EUVIMED